{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:25:19Z","timestamp":1783113919745,"version":"3.54.6"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018627","name":"Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China","doi-asserted-by":"publisher","award":["2025KJJ024"],"award-info":[{"award-number":["2025KJJ024"]}],"id":[{"id":"10.13039\/501100018627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110023","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:42:16Z","timestamp":1779428536000},"page":"110023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazine derivatives as potent SYK inhibitors for solid tumor therapy"],"prefix":"10.1016","volume":"179","author":[{"given":"Jie","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110023_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117905","article-title":"Pharmacologically targeting protein lactylation to overcome cancer drug resistance","volume":"296","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110023_bb0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cca.2022.01.023","article-title":"Surface plasmon resonance: a promising approach for label-free early cancer diagnosis","volume":"527","author":"Gade","year":"2022","journal-title":"Clin. Chim. Acta"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110023_bb0015","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41577-023-00877-7","article-title":"Protein kinases: drug targets for immunological disorders","volume":"23","author":"Castelo-Soccio","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2026.110023_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103547","article-title":"Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor","volume":"95","author":"Wang","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110023_bb0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110023_bb0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cmet.2020.12.015","article-title":"The evolving landscape of noncanonical functions of metabolic enzymes in Cancer and other pathologies","volume":"33","author":"Xu","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.bioorg.2026.110023_bb0035","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1146\/annurev-immunol-042617-053344","article-title":"Multidomain control over TEC kinase activation state Tunes the T cell response","volume":"36","author":"Andreotti","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2026.110023_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117514","article-title":"Review and prospects of targeted therapies for spleen tyrosine kinase (SYK)","volume":"96","author":"Wang","year":"2023","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110023_bb0045","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/jpet.116.233155","article-title":"BI 1002494, a novel potent and selective Oral spleen tyrosine kinase inhibitor, displays differential potency in human basophils and B cells","volume":"357","author":"Lamb","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110023_bb0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1574888X13666180723104340","article-title":"Classic and novel signaling pathways involved in Cancer: targeting the NF-\u03baB and Syk signaling pathways","volume":"14","author":"Tang","year":"2019","journal-title":"Curr. Stem Cell Res. Ther."},{"issue":"23","key":"10.1016\/j.bioorg.2026.110023_bb0055","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1038\/s41388-019-0734-5","article-title":"Targeting SYK signaling in myeloid cells protects against liver fibrosis and hepatocarcinogenesis","volume":"38","author":"Torres-Hernandez","year":"2019","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110023_bb0060","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/1878-0261.12783","article-title":"Platelets are recruited to hepatocellular carcinoma tissues in a CX3CL1-CX3CR1 dependent manner and induce tumour cell apoptosis","volume":"14","author":"Miao","year":"2020","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110023_bb0065","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/jcb.25625","article-title":"Suppression of spleen tyrosine kinase (Syk) by histone deacetylation promotes, whereas BAY61-3606, a synthetic Syk inhibitor abrogates colonocyte apoptosis by ERK activation","volume":"118","author":"Dasgupta","year":"2017","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110023_bb0070","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/iid3.449","article-title":"Comprehensive analysis of Syk gene methylation in colorectal cancer","volume":"9","author":"Bu","year":"2021","journal-title":"Immun. Inflamm. Dis."},{"issue":"22","key":"10.1016\/j.bioorg.2026.110023_bb0075","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1111\/febs.14665","article-title":"Spleen tyrosine kinase SYK (L) interacts with YY1 and coordinately suppresses SNAI2 transcription in lung cancer cells","volume":"285","author":"Gao","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.bioorg.2026.110023_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110079","article-title":"Regulatory interplay between Vav1, Syk and \u03b2-catenin occurs in lung cancer cells","volume":"86","author":"Boudria","year":"2021","journal-title":"Cell. Signal."},{"issue":"28","key":"10.1016\/j.bioorg.2026.110023_bb0085","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1038\/s41388-018-0241-0","article-title":"Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway","volume":"37","author":"Yu","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110023_bb0090","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ebiom.2019.08.055","article-title":"Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer","volume":"47","author":"Yu","year":"2019","journal-title":"eBioMedicine"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110023_bb0095","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/13543784.2022.2040014","article-title":"Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases","volume":"31","author":"Tang","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110023_bb0100","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bjd.17932","article-title":"The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study","volume":"181","author":"Bissonnette","year":"2019","journal-title":"Br. J. Dermatol."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110023_bb0105","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.bmcl.2015.03.072","article-title":"Design, synthesis of diaminopyrimidine inhibitors targeting IgE- and IgG-mediated activation of fc receptor signaling","volume":"25","author":"Argade","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110023_bb0110","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1002\/art.38851","article-title":"Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"66","author":"Weinblatt","year":"2014","journal-title":"Arthritis Rheum."},{"issue":"41","key":"10.1016\/j.bioorg.2026.110023_bb0115","doi-asserted-by":"crossref","first-page":"43881","DOI":"10.18632\/oncotarget.6316","article-title":"Cerdulatinib, a novel dual SYK\/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma","volume":"6","author":"Ma","year":"2015","journal-title":"Oncotarget"},{"issue":"15_suppl","key":"10.1016\/j.bioorg.2026.110023_bb0120","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8531","article-title":"Phase 1 open-label dose escalation study of the dual SYK\/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed\/refractory B-cell malignancies: safety profile and clinical activity","volume":"33","author":"Flinn","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110023_bb0125","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(23)00034-0","article-title":"Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b\/2 study","volume":"10","author":"Liu","year":"2023","journal-title":"Lancet. Haematol."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110023_bb0130","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1021\/jm500228a","article-title":"Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase","volume":"57","author":"Currie","year":"2014","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110023_bb0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s41927-021-00178-3","article-title":"Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis","volume":"5","author":"Pohlmeyer","year":"2021","journal-title":"BMC. Rheumatol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110023_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001490","article-title":"Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy","volume":"6","author":"Baker","year":"2020","journal-title":"RMD. Open"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110023_bb0145","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/rheumatology\/keab685","article-title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","volume":"61","author":"Werth","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110023_bb0150","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1021\/acsmedchemlett.9b00621","article-title":"Discovery of Lanraplenib (GS-9876): a once-daily spleen tyrosine kinase inhibitor for autoimmune diseases","volume":"11","author":"Blomgren","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110023_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2026.129543","article-title":"A comprehensive review on 1,2,4-Triazole: synthesis, properties and therapeutic potential","volume":"305","author":"Kumar","year":"2026","journal-title":"Talanta"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110023_bb0160","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1021\/acs.jmedchem.4c00652","article-title":"Triazoles in medicinal chemistry: physicochemical properties, Bioisosterism, and application","volume":"67","author":"Guan","year":"2024","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2026.110023_bb0165","doi-asserted-by":"crossref","first-page":"25416","DOI":"10.1021\/acs.jmedchem.5c02404","article-title":"Novel Isoidide subunit-containing xanthine oxidase inhibitors with potent Hypouricemic effects","volume":"68","author":"Zeng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110023_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115242","article-title":"Design, synthesis, and biological evaluation of novel dihydropteridone derivatives possessing oxadiazoles moiety as potent inhibitors of PLK1","volume":"251","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"W1","key":"10.1016\/j.bioorg.2026.110023_bb0175","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:11:37Z","timestamp":1783113097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826005596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S0045206826005596"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110023","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazine derivatives as potent SYK inhibitors for solid tumor therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110023"}}